Marshall Wace LLP Increases Stake in Annexon, Inc. (NASDAQ:ANNX)

Marshall Wace LLP grew its position in Annexon, Inc. (NASDAQ:ANNX) by 436.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,693,665 shares of the company’s stock after acquiring an additional 1,378,053 shares during the period. Marshall Wace LLP owned about 1.83% of Annexon worth $8,299,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Ameritas Investment Partners Inc. boosted its holdings in Annexon by 78.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company’s stock valued at $48,000 after purchasing an additional 2,949 shares in the last quarter. Comerica Bank acquired a new position in Annexon during the first quarter worth $72,000. Victory Capital Management Inc. purchased a new position in Annexon in the second quarter worth $51,000. Principal Financial Group Inc. purchased a new position in Annexon in the second quarter worth $56,000. Finally, ProShare Advisors LLC acquired a new stake in Annexon in the first quarter valued at $87,000.

Annexon Trading Up 0.3 %

NASDAQ:ANNX opened at $6.14 on Monday. Annexon, Inc. has a twelve month low of $1.57 and a twelve month high of $8.40. The company has a market capitalization of $567.42 million, a P/E ratio of -4.18 and a beta of 1.28. The firm has a 50-day moving average price of $6.09 and a two-hundred day moving average price of $5.63.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.23). On average, equities research analysts predict that Annexon, Inc. will post -0.97 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Annexon in a report on Tuesday, August 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a report on Monday, September 9th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Annexon in a research note on Tuesday, August 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $15.80.

Insider Transactions at Annexon

In related news, EVP Ted Yednock sold 4,500 shares of the stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $7.10, for a total transaction of $31,950.00. Following the sale, the executive vice president now owns 71,365 shares of the company’s stock, valued at $506,691.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 17,388 shares of company stock valued at $107,072 over the last three months. 12.67% of the stock is currently owned by insiders.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.